anti-her2 therapy for breast cancer ana lilia castruita-avila, m.d.
Published 5 years ago • 443 plays • Length 12:40Download video MP4
Download video MP3
Similar videos
-
0:45
dr. hamilton on using pcr to classify risk in her2 breast cancer
-
5:01
neoadjuvant lapatinib in her2 early breast cancer
-
2:03
dr. lori goldstein on neoadjuvant treatment for her2 breast cancer
-
2:15
dr. hurvitz on neoadjuvant therapy for her2 breast cancer
-
5:06
factors in deciding treatment for hr breast cancer
-
24:33
20221005 talk with a doc - breast cancer
-
2:51
breast cancer: extended adjuvant therapy and cost factors
-
3:12
combination treatments for premenopausal breast cancer: endocrine therapy and ovarian suppression
-
2:33
challenges with neoadjuvant endocrine therapy in breast cancer
-
0:49
dr. tolaney on the current treatment landscape for her2 breast cancer
-
4:56
neoadjuvant talazoparib active in brca-mutated early breast cancer | jennifer litton
-
6:59
her2 bc: selection and management of neoadjuvant therapy
-
7:37
dr. tolaney highlights new breast cancer combination therapies
-
7:11
case 1: adjuvant therapy for residual disease in her2 breast cancer
-
2:36
identifying breast cancers that are resistant to treatment and reducing resistance.
-
1:49
dr. rahman on pertuzumab and neratinib in her2 breast cancer
-
15:51
considerations for pre-operative therapy to optimize care of women with her2 breast cancer
-
1:47
evaluating the role of neoadjuvant endocrine therapy in breast cancer
-
51:56
new & supporting data for optimizing therapy in her2 breast cancer | dr. kaklamani and dr. o’regan